A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the
safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of
ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.